Skip to main content

Table 3 Comparison of plasma miRNA levels in patients with cervical lesions of different grades

From: Plasma expression of miRNA-21, − 214, −34a, and -200a in patients with persistent HPV infection and cervical lesions

Area

group(2-CT, x ± s)

normal controls

persistent hr-HPV

CIN1

CIN1-

CIN2

CIN3

cancer

CIN2+

Number of cases

42

31

19

92

54

71

15

140

miRNA-21

1.96 ± 3.08

1.69 ± 2.72

3.79 ± 6.17

2.25 ± 3.93

6.88 ± 11.25

5.37 ± 6.25

6.87 ± 12.99

6.12 ± 9.37

miRNA-214

1.68 ± 3.40

2.20 ± 3.38

0.63 ± 1.79

1.63 ± 3.20

0.31 ± 1.29

0.30 ± 1.28

0.23 ± 0.31

0.29 ± 1.22

miRNA-200a

0.47 ± 0.62

0.78 ± 0.96

0.21 ± 0.35

0.52 ± 0.74

0.24 ± 0.41

0.22 ± 0.27

0.18 ± 0.19

0.22 ± 0.32

miRNA-34a

1.62 ± 2.64

2.24 ± 2.94

0.72 ± 1.39

1.64 ± 2.62

0.77 ± 1.34

0.78 ± 1.78

0.45 ± 0.27

0.74 ± 1.53

  1. In Table 3, 42 normal controls, 31 persistent HPV patients and 19 CIN1 patients were combined to obtain 92 CIN1- subjects, and 54 CIN2, 71 CIN3 and 15 cancer patients were combined for a total of 140 patients in the CIN2+ group
  2. Plasma miRNA levels in the CIN1- group were significantly different from those in the CIN2+ group, p < 0.01 (miRNA21, t = 4.34, p = 0.000; miRNA214, t = 4.18, p = 0.0001; miRNA200a, t = 3.67, p = 0.0002; miRNA, t = 2.98, p = 0.0017)